PBE

Featured

Three ETFs to Play the Outperforming Biotech Sector

By Tom LydonAugust 19, 2013

Featured

Choosing the Right Biotech ETF Exposure

By Tom LydonApril 20, 2012

Featured

Biotech ETFs Mixed After Gilead Subpoena

By Tom LydonJune 13, 2011

Featured

5 Biotechnology ETFs to Play Innovation

By Tom LydonFebruary 22, 2011

Featured

Why Health Care ETFs May Be In the Clear

By Tom LydonNovember 10, 2010

Featured

5 Things That Drive Biotech ETFs

By Tom LydonOctober 21, 2010

Featured

Biotech ETFs:The Better Way to Play

By Tom LydonOctober 11, 2010

Featured

Biotech ETFs: 5 Ways to Play Innovation

By Tom LydonAugust 8, 2010

Featured

5 Biotech ETFs If You’re Bullish

By Tom LydonJune 25, 2010

Featured

Biotech ETFs: Where the Future Lies

By Tom LydonFebruary 5, 2010

Featured

Biotechnology: Why ETFs Suit the Sector

By Tom LydonNovember 19, 2009

Featured

What Biotechnology ETFs Need to Thrive

By Tom LydonSeptember 4, 2009

Featured

7 Reasons Biotechnology ETFs Could Succeed

By Tom LydonAugust 6, 2009

Featured

ETF Spotlight: PowerShares Dynamic Biotech & Genome (PBE)

By Tom LydonJuly 29, 2009

Featured

Biotech Sector and ETFs Get a Lifeline

By Tom LydonJuly 8, 2009

Featured

Health Care Reform and Biotech ETFs: Will There Be Opportunities?

By Tom LydonJune 27, 2009

Featured

Why Biotech ETFs May Be the Better Choice

By Tom LydonJune 17, 2009

Featured

Can Obama’s Push Reignite Biotech and Health Care ETFs?

By Tom LydonJune 15, 2009